Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258538 | 0.81 | PTPN1 (0.58) | PTGS2PTGS1MAOBHSPD1HSPE1 | |
| SCHEMBL4258531 | 0.81 | PTPN1 (0.58) | PTGS2PTGS1MAOBHSPD1HSPE1 | |
| SCHEMBL3667180 | 0.77 | PTPN1 (0.73) | PTGS2PTGS1MAOBHSPD1HSPE1 | |
| SCHEMBL3667178 | 0.77 | PTPN1 (0.73) | PTGS2PTGS1MAOBHSPD1HSPE1 | |
| SCHEMBL3675450 | 0.75 | PTGS2 (0.71) | PTGS2PTGS1MAOBCYP19A1APP | |
| SCHEMBL3675448 | 0.75 | PTGS2 (0.71) | PTGS2PTGS1MAOBCYP19A1APP | |
| SCHEMBL12644210 | 0.73 | KMT2A (0.55) | PTGS2PTGS1MAOBALDH1A1KMT2A | |
| SCHEMBL9828022 | 0.72 | ALDH1A1 (0.63) | PTGS2PTGS1MAOBCYP19A1ALDH1A1 | |
| SCHEMBL9828020 | 0.72 | ALDH1A1 (0.63) | PTGS2PTGS1MAOBCYP19A1ALDH1A1 | |
| SCHEMBL3672520 | 0.72 | PTGS2 (0.75) | PTGS2PTGS1CYP19A1HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629375-B2 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | GALILEO PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113416-A1 | Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods | HSF1, HMOX1, NQO1 | PTGS2 181/4885PTGS1 183/4885MAOB 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.